Eli Lilly demonstrates that 2 antibodies beat 1 for guarding against severe Covid-19. But can that solve the first antibody’s problem amid slow uptake?
It seems safe to say that two antibodies are better than one.
Eli Lilly released the largest results yet on Tuesday for their Covid-19 neutralizing antibody cocktail, announcing that the combo reduced deaths and hospitalizations in coronavirus patients by 70%. Across 1,000 patients, there were 11 such events in the treatment group and 36 in the placebo group.
The breakdown for deaths alone was even starker: 10 in the placebo group and 0 in the treatment group. Lilly added that the drug hit secondary endpoints for reducing viral load and alleviating symptoms, although they did not disclose numbers.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.